or Try an Advanced Search...

    Technical Analysis for AMIX - Autonomix Medical, Inc.

    Grade Last Price % Change Price Change
    F 2.70 1.12% 0.03
    AMIX closed up 1.12 percent on Tuesday, May 14, 2024, on 82 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent N/A Down Down
    Historical AMIX trend table...
    Date Alert Name Type % Chg
    Hammer Candlestick Bullish 0.00%
    Calm After Storm Range Contraction 0.00%
    NR7 Range Contraction 0.00%
    Gapped Up Strength 0.00%
    Lower Bollinger Band Touch Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    Calm After Storm Range Contraction 1.12%
    Stochastic Reached Oversold Weakness 1.12%
    Down 3 Days in a Row Weakness 1.12%
    Gapped Down Weakness 1.12%
    Older End-of-Day Signals for AMIX ...

       Recent Intraday Alerts

    Alert Time
    Down 5% about 19 hours ago
    Down 3% about 19 hours ago
    Fell Below Lower Bollinger Band about 19 hours ago
    Fell Below Previous Day's Low about 19 hours ago
    Down 2 % about 19 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    AMIX Chart by TradingView
    Basic chart:

    Profile

    • Earnings date: Unknown
    Autonomix Medical is a developer of a novel technology designed to bring clarity to minimally invasive renal denervation to treat heart disease. Its technology is used to develop minimally invasive neural monitoring and treatment devices for next-generation neuromodulation therapies that enable medical practitioners to accurately assess and treat peripheral and neural mediated disease. The company develops a proprietary microchip, hardware, and software which can be integrated into a catheter or other device to dramatically improve electrophysiologic signal fidelity and simplify data analysis. It was founded in 2014 and is headquartered in Excelsior, Minnesota.
    Classification
    Sector: Healthcare
    Industry: Medical Devices
    Keywords: Catheter Interventional Radiology Neuromodulation Neurophysiology Heart Disease Minimally Invasive Procedure Neuropsychology Hardware Treatment Devices

    Is AMIX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 25 Autonomix Enters into Agreement with NoiseFigure Research, Inc. to Develop Next Generation of its Proprietary Microchip
    Apr 24 Autonomix to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar
    Apr 16 Autonomix gets patent covering proprietary catheter-based technology
    Apr 16 Autonomix Announces Issuance of U.S. Patent Covering Proprietary Catheter-Based Technology for the Treatment of Cancer Related Pain
    Apr 15 Autonomix Medical Inc. Covered in Benzinga Article Highlighting Innovative Nerve Treatment Technology
    Apr 8 Autonomix to Participate in the Virtual Investor Lunch Break: The Team Behind the AMIX Ticker
    Mar 20 Autonomix (NASDAQ: AMIX) to Present at the Benzinga Virtual Healthcare Summit 2024
    Mar 19 Autonomix Appoints Jennifer Cook as Chief Business Officer
    Mar 14 Autonomix Completes First Three Patient Procedures in Human Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer Market
    Mar 6 Autonomix Enrolls First Patients in Human Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer Market
    See more AMIX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 7.6
    52 Week Low 2.5
    Average Volume 52,134
    200-Day Moving Average 0.00
    50-Day Moving Average 3.01
    20-Day Moving Average 3.05
    10-Day Moving Average 3.00
    Average True Range 0.34
    RSI (14) 39.76
    ADX 12.28
    +DI 15.95
    -DI 21.06
    Chandelier Exit (Long, 3 ATRs) 2.78
    Chandelier Exit (Short, 3 ATRs) 3.53
    Upper Bollinger Bands 3.47
    Lower Bollinger Band 2.64
    Percent B (%b) 0.08
    BandWidth 27.27
    MACD Line -0.07
    MACD Signal Line -0.03
    MACD Histogram -0.0418
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 3.08
    Resistance 3 (R3) 3.06 2.91 3.01
    Resistance 2 (R2) 2.91 2.82 2.92 2.99
    Resistance 1 (R1) 2.81 2.76 2.74 2.83 2.97
    Pivot Point 2.66 2.66 2.63 2.67 2.66
    Support 1 (S1) 2.56 2.57 2.49 2.58 2.43
    Support 2 (S2) 2.41 2.51 2.42 2.41
    Support 3 (S3) 2.31 2.41 2.39
    Support 4 (S4) 2.33